ArticleScientific reports2022

Trough anti-Xa activity after intermediate dose nadroparin for thrombosis prophylaxis in critically ill patients with COVID-19 and acute kidney injury.

R J Eck et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.